The Goldman Sachs Group Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock

Biogen (NASDAQ:BIIB) had its target price lifted by stock analysts at The Goldman Sachs Group from $231.00 to $238.00 in a research note issued to investors on Friday,MarketScreener reports. The firm presently has a “buy” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price target indicates a potential upside of 29.08% from the stock’s previous close.

Other research analysts have also recently issued reports about the stock. Canaccord Genuity Group increased their price target on shares of Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a research report on Wednesday, April 1st. Truist Financial lowered their price objective on shares of Biogen from $193.00 to $189.00 and set a “hold” rating for the company in a report on Monday, April 13th. Wolfe Research set a $231.00 price objective on shares of Biogen in a research note on Monday, February 9th. Tudor Pickering set a $201.00 target price on shares of Biogen in a report on Monday, February 9th. Finally, Stifel Nicolaus boosted their price target on shares of Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Fourteen analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $211.81.

Biogen Trading Down 1.9%

Shares of BIIB stock opened at $184.38 on Friday. The business has a 50-day moving average price of $185.13 and a two-hundred day moving average price of $175.19. Biogen has a 12-month low of $115.25 and a 12-month high of $202.41. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The firm has a market cap of $27.06 billion, a P/E ratio of 20.93, a price-to-earnings-growth ratio of 2.51 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating the consensus estimate of $1.61 by $0.38. The firm had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company’s revenue was down 7.2% on a year-over-year basis. During the same period in the prior year, the company earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities analysts anticipate that Biogen will post 15.77 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the sale, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.18% of the company’s stock.

Institutional Trading of Biogen

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Biogen by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock valued at $3,070,514,000 after acquiring an additional 157,857 shares in the last quarter. Geode Capital Management LLC raised its holdings in Biogen by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock worth $736,435,000 after purchasing an additional 130,618 shares in the last quarter. Norges Bank bought a new position in Biogen in the 4th quarter worth $464,408,000. Invesco Ltd. lifted its position in shares of Biogen by 4.2% in the 3rd quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock worth $338,731,000 after purchasing an additional 98,001 shares during the period. Finally, Morgan Stanley boosted its stake in shares of Biogen by 3.3% during the 4th quarter. Morgan Stanley now owns 2,325,013 shares of the biotechnology company’s stock valued at $409,180,000 after purchasing an additional 73,478 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen struck a China deal to develop felzartamab as a domestically produced anti‑CD38 therapy for multiple myeloma — this expands its China footprint and could open a meaningful growth market. Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal
• Positive Sentiment: UBS upgraded Biogen, and JPMorgan raised its price target to $185 (still a Neutral rating) — these moves provide some analyst validation for the story but stop short of a full buy case. UBS upgrades Biogen (BIIB) JPMorgan raises price target
• Neutral Sentiment: Q1 earnings preview pieces highlight that new products (Skyclarys, Zurzuvae) are driving growth but legacy MS sales face competitive pressure — outcome of Q1 will be a key catalyst and remains uncertain. Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
• Neutral Sentiment: Rothschild & Co Redburn issued EPS estimates and raised its price target to $180 while maintaining a Neutral rating — adds supply of modeled forecasts but not a bullish call. Rothschild & Co Redburn estimates and target
• Negative Sentiment: Short interest rose to ~4.41M shares as of April 15 (+15.4% vs. March 31), representing about 3.0% of float and a short‑interest ratio ~3.1 days — higher shorting can amplify downward pressure around weak news. (Note: an April 24 data point showing zero shares appears to be a reporting anomaly.)
• Negative Sentiment: Wolfe Research trimmed Q1 and Q2 EPS estimates (and trimmed Q2 guidance), signaling risk to near‑term earnings expectations and likely contributing to negative trading sentiment.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.